The Food and Drug Administration cleared the way for Tonix Pharmaceuticals to begin a Phase II study of the company’s therapeutic candidate, which intends to prevent migraine headaches.
If you are not happy with the results below please do another search
50 search results for:
The U.S. Food and Drug Administration greenlit Aadi Bioscience’s Fyarro for treating a rare and aggressive form of cancer that disproportionately affects women.
Glympse Bio has developed a liquid biopsy with the potential to diagnose and monitor non-alcoholic steatohepatitis (NASH) with significantly higher accuracy and less invasiveness than needle biopsies, according to a late-breaking presentation at the American Association for the Study of Liver Disease (AASLD) annual The Liver Meeting.
New discovery facilities have been launched in the biotech space by AstraZeneca, BeiGene, and NeuExcell Therapeutics.
An experimental chewing gum containing a protein that “traps” coronavirus particles could limit the amount of virus in saliva and help curb transmission when infected people are talking, breathing or coughing, researchers believe. In other news, protection against Covid-19 from an mRNA vaccine – either the Moderna or Pfizer/BioNTech shots – may last longer after the booster dose than after the original two-shot regimen, researchers speculated based on the results of a small new study.
JAMA Neurology published a study by researchers looking at cases of amyloid-related imaging abnormalities (ARIA-E) in two Phase III trials for Biogen’s Alzheimer’s drug Aduhelm (aducanumab).
Arrowhead Pharmaceuticals Inc. on November 22 entered a drug development deal with GlaxoSmithKline Plc under which the British drugmaker will develop and market Arrowhead’s potential treatment for patients with fatty liver disease NASH.
Connect Biopharmaceuticals – based in Taicang, Suzhou, China and San Diego – reported positive topline data from the company’s Phase II trial of CBP-201 for adults with moderate-to-severe atopic dermatitis (AD).
Pfizer said the company’s Covid-19 vaccine, developed with BioNTech, demonstrated 100 percent effectiveness in the 12-15 year age group after four months. In other news, the U.S. Food and Drug Administration said that it could take over 55 years for the regulatory agency to review and release a complete report on the vaccine-related documentation the FDA currently holds in response to a lawsuit filed by scientists demanding to see the complete records.
Neurocrine Biosciences has partnered with Sosei Group Corporation to develop treatments that would address dementia, schizophrenia, and other types of neuropsychiatric disorders.